4-1004393-A-T
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM5_SupportingPS3_SupportingPM2PM4PM3_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000203.5:c.1962A>T in IDUA is a stop-loss variant, predicted to alter the stop codon (p.Ter654Cys), resulting in an increase in the length of the protein (PM1). The variant was identified in homozygosity in a patient with clinical symptoms consistent with MPS 1 and positive urine spot test for GAGs (PM3_Supporting). IDUA activity was deficient. However, because the patient is also homozygous for a benign "pseudodeficiency" variant (c.1225G>C, p.Gly409Arg), there is insufficient data to apply PP4 (PMID:8328452). When expressed in COS-1 cells, the p.Ter654Cys variant resulted in 2% normal activity (PMID:8328452) (PS3_Supporting). Three other variants in the stop codon of IDUA have been reported, one of which, c.1960T>C (p.Ter654Arg) (Bertola et al, PMID:21394825; Ngiwsara et al, PMID:29282708), has been classified as likely pathogenic by the ClinGen LD VCEP (PM5_Supporting). The other variants are c.1960T>G (p.Ter654Gly) (Tieu et al, 1995, PMID:7550232), and c.1960T>A (p.Ter654Arg) (Thomas et al, PMID:33301762). There is a ClinVar entry for the variant (Variation ID: 242721). In summary, this variant meets the criteria to be classified as likely pathogenic for mucopolysaccharidosis type 1. IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications 1.0.0): PM4, PS3_Supporting, PM2_Supporting, PM3_Supporting, PM5_Supporting.(Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 5, 2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA353725/MONDO:0001586/091
Frequency
Consequence
NM_000203.5 stop_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IDUA | ENST00000514224.2 | c.1962A>T | p.Ter654Cysext*? | stop_lost | Exon 14 of 14 | 2 | NM_000203.5 | ENSP00000425081.2 | ||
IDUA | ENST00000247933.9 | c.1962A>T | p.Ter654Cysext*? | stop_lost | Exon 14 of 14 | 1 | ENSP00000247933.4 | |||
IDUA | ENST00000514698.5 | n.2073A>T | non_coding_transcript_exon_variant | Exon 11 of 11 | 5 | |||||
IDUA | ENST00000652070.1 | n.2018A>T | non_coding_transcript_exon_variant | Exon 13 of 13 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Mucopolysaccharidosis type 1 Pathogenic:1
The NM_000203.5:c.1962A>T in IDUA is a stop-loss variant, predicted to alter the stop codon (p.Ter654Cys), resulting in an increase in the length of the protein (PM1). The variant was identified in homozygosity in a patient with clinical symptoms consistent with MPS 1 and positive urine spot test for GAGs (PM3_Supporting). IDUA activity was deficient. However, because the patient is also homozygous for a benign "pseudodeficiency" variant (c.1225G>C, p.Gly409Arg), there is insufficient data to apply PP4 (PMID: 8328452). When expressed in COS-1 cells, the p.Ter654Cys variant resulted in 2% normal activity (PMID: 8328452) (PS3_Supporting). Three other variants in the stop codon of IDUA have been reported, one of which, c.1960T>C (p.Ter654Arg) (Bertola et al, PMID: 21394825; Ngiwsara et al, PMID: 29282708), has been classified as likely pathogenic by the ClinGen LD VCEP (PM5_Supporting). The other variants are c.1960T>G (p.Ter654Gly) (Tieu et al, 1995, PMID: 7550232), and c.1960T>A (p.Ter654Arg) (Thomas et al, PMID: 33301762). There is a ClinVar entry for the variant (Variation ID: 242721). In summary, this variant meets the criteria to be classified as likely pathogenic for mucopolysaccharidosis type 1. IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications 1.0.0): PM4, PS3_Supporting, PM2_Supporting, PM3_Supporting, PM5_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 5, 2024) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at